The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | ZUMA-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk LBCL
Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the design and results of ZUMA-12, a Phase II clinical trial evaluating axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients with high-risk large B-cell lymphoma (LBCL) (NCT03761056). The complete response (CR) rate was 78% and the best overall response rate (ORR) was 78%. After a median follow-up of 16 months, 73% of patients remained in remission. In addition, there were no new safety signals observed with axi-cel treatment compared to previous studies. Interestingly, chimeric antigen receptor T-cell (CAR-T) expansion was greater in the first-line setting than in previous clinical trials evaluating axi-cel in patients who had received three or more prior lines of therapy. This data suggests that axi-cel is an effective strategy in the first-line setting, but further studies evaluating this CAR-T therapy and comparing it to chemoimmunotherapy are required. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
